Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia.

Gutierrez A, Dahlberg SE, Neuberg DS, Zhang J, Grebliunaite R, Sanda T, Protopopov A, Tosello V, Kutok J, Larson RS, Borowitz MJ, Loh ML, Ferrando AA, Winter SS, Mullighan CG, Silverman LB, Chin L, Hunger SP, Sallan SE, Look AT.

J Clin Oncol. 2010 Aug 20;28(24):3816-23. doi: 10.1200/JCO.2010.28.3390. Epub 2010 Jul 19.

PMID:
20644084
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Absence of biallelic TCRγ deletion predicts induction failure and poorer outcomes in childhood T-cell acute lymphoblastic leukemia.

Yang YL, Hsiao CC, Chen HY, Lin KH, Jou ST, Chen JS, Chang TK, Sheen JM, Yu SL, Lu MY, Cheng CN, Wu KH, Wang SC, Wang JD, Chang HH, Lin SR, Lin SW, Lin DT.

Pediatr Blood Cancer. 2012 Jun;58(6):846-51. doi: 10.1002/pbc.24021. Epub 2011 Dec 16.

PMID:
22180181
[PubMed - indexed for MEDLINE]
3.

Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.

Dibenedetto SP, Lo Nigro L, Mayer SP, Rovera G, Schilirò G.

Blood. 1997 Aug 1;90(3):1226-32.

PMID:
9242556
[PubMed - indexed for MEDLINE]
Free Article
4.

Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.

Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, Wolff L, Uckun FM, Gaynon PS.

N Engl J Med. 1998 Jun 4;338(23):1663-71.

PMID:
9614257
[PubMed - indexed for MEDLINE]
Free Article
5.
6.

Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.

Tzortzatou-Stathopoulou F, Papadopoulou AL, Moschovi M, Botsonis A, Tsangaris GT.

J Pediatr Hematol Oncol. 2001 Dec;23(9):591-7. Review.

PMID:
11902303
[PubMed - indexed for MEDLINE]
7.

Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.

Eckert C, von Stackelberg A, Seeger K, Groeneveld TW, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Escherich G, Henze G.

Eur J Cancer. 2013 Apr;49(6):1346-55. doi: 10.1016/j.ejca.2012.11.010. Epub 2012 Dec 19.

PMID:
23265714
[PubMed - indexed for MEDLINE]
8.

Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.

Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V, Pieters R, Stary J, Escherich G, Campbell M, Li CK, Vora A, Aricò M, Röttgers S, Saha V, Valsecchi MG.

Lancet Oncol. 2012 Sep;13(9):936-45. doi: 10.1016/S1470-2045(12)70377-7. Epub 2012 Aug 14.

PMID:
22898679
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

[A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia].

Wang L, Zhang LP, Li ZG, Cheng YF, Tian KG, Lu AD.

Zhonghua Er Ke Za Zhi. 2005 Mar;43(3):170-3. Chinese.

PMID:
15833185
[PubMed - indexed for MEDLINE]
10.

[Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].

Lu XT.

Beijing Da Xue Xue Bao. 2013 Apr 18;45(2):327-32. Review. Chinese.

PMID:
23591360
[PubMed - indexed for MEDLINE]
Free Article
11.

Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study.

Oudot C, Auclerc MF, Levy V, Porcher R, Piguet C, Perel Y, Gandemer V, Debre M, Vermylen C, Pautard B, Berger C, Schmitt C, Leblanc T, Cayuela JM, Socie G, Michel G, Leverger G, Baruchel A.

J Clin Oncol. 2008 Mar 20;26(9):1496-503. doi: 10.1200/JCO.2007.12.2820.

PMID:
18349402
[PubMed - indexed for MEDLINE]
Free Article
12.

Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma.

Callens C, Baleydier F, Lengline E, Ben Abdelali R, Petit A, Villarese P, Cieslak A, Minard-Colin V, Rullier A, Moreau A, Baruchel A, Schmitt C, Asnafi V, Bertrand Y, Macintyre E.

J Clin Oncol. 2012 Jun 1;30(16):1966-73. doi: 10.1200/JCO.2011.39.7661. Epub 2012 Apr 30.

PMID:
22547598
[PubMed - indexed for MEDLINE]
Free Article
13.

Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: a report from Children's Oncology Group Study CCG-1962.

Avramis IA, Panosyan EH, Dorey F, Holcenberg JS, Avramis VI; Children's Oncology Group.

Clin Cancer Res. 2006 Dec 1;12(23):6978-84.

PMID:
17145817
[PubMed - indexed for MEDLINE]
Free Article
14.

Outcomes after induction failure in childhood acute lymphoblastic leukemia.

Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A, Conter V, Otten J, Ohara A, Versluys AB, Escherich G, Heyman M, Silverman LB, Horibe K, Mann G, Camitta BM, Harbott J, Riehm H, Richards S, Devidas M, Zimmermann M.

N Engl J Med. 2012 Apr 12;366(15):1371-81. doi: 10.1056/NEJMoa1110169.

PMID:
22494120
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.

Cavé H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E.

N Engl J Med. 1998 Aug 27;339(9):591-8.

PMID:
9718378
[PubMed - indexed for MEDLINE]
Free Article
16.

Acute lymphoblastic leukemia in a developing country: preliminary results of a nonrandomized clinical trial in El Salvador.

Bonilla M, Moreno N, Marina N, deReyes G, Shurtleff SA, Downing JR, Behm FG, Harrison PL, Ribeiro RC, Peña O, Crist WM, Antillon FG.

J Pediatr Hematol Oncol. 2000 Nov-Dec;22(6):495-501.

PMID:
11132215
[PubMed - indexed for MEDLINE]
17.

Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.

Ribera JM, Ortega JJ, Oriol A, Granada I, Hernández-Rivas JM, Parody R, Bethencourt C, Rivas C, Bastida P, del Potro E, González-Valentín ME, Moreno MJ, Besalduch J, Fernández-Calvo J, Tormo M, Arias J, Molinés A, Sanz MA, Maldonado J, Millá F, Feliu E, San Miguel JF; PETHEMA Group, Spanish Society of Hematology.

Haematologica. 2002 Feb;87(2):154-66.

PMID:
11836166
[PubMed - indexed for MEDLINE]
Free Article
18.

Improved prognosis for older adolescents with acute lymphoblastic leukemia.

Pui CH, Pei D, Campana D, Bowman WP, Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Coustan-Smith E, Jeha S, Cheng C, Metzger ML, Bhojwani D, Inaba H, Raimondi SC, Onciu M, Howard SC, Leung W, Downing JR, Evans WE, Relling MV.

J Clin Oncol. 2011 Feb 1;29(4):386-91. doi: 10.1200/JCO.2010.32.0325. Epub 2010 Dec 20.

PMID:
21172890
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.

Ochs J, Rivera GK, Pollock BH, Buchanan G, Crist W, Freeman AI.

Cancer. 1990 Oct 15;66(8):1671-7.

PMID:
2208021
[PubMed - indexed for MEDLINE]
20.

Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study.

Uckun FM, Yang Z, Sather H, Steinherz P, Nachman J, Bostrom B, Crotty L, Sarquis M, Ek O, Zeren T, Tubergen D, Reaman G, Gaynon P.

Blood. 1997 May 15;89(10):3769-77.

PMID:
9160683
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk